Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

doi:10.1200/JCO.2017.75.7740

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jun 2018

Teo Min Yuen, Seier Kenneth, Ostrovnaya Irina, Regazzi Ashley M, Kania Brooke E, Moran Meredith M, Cipolla Catharine K, Bluth Mark J, Chaim Joshua, Al-Ahmadie Hikmat, Snyder Alexandra, Carlo Maria I, Solit David B, Berger Michael F, Funt Samuel, Wolchok Jedd D, Iyer Gopa, Bajorin Dean F, Callahan Margaret K, Rosenberg Jonathan E

Abstract excerpt

Purpose Alterations in DNA damage response and repair (DDR) genes are associated with increased mutation load and improved clinical outcomes in platinum-treated metastatic urothelial carcinoma. We examined the relationship between DDR alterations and response to PD-1/PD-L1 blockade. Methods Detailed demographic, treatment response, and long-term outcome data were collected on patients with metastatic urothelial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to B7-H1 Antigen

Share to DNA Damage

Share to DNA Repair

Share to Programmed Cell Death 1 Receptor

Share to Progression-Free Survival

Share to Urologic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 29489427
DOI: 10.1200/JCO.2017.75.7740
PMCID: PMC6366295

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.PMID 29489427Read ↗

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.Semantic proximity Read ↗

Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.Semantic proximity Read ↗

Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."Semantic proximity Read ↗

Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assaysSemantic proximity Read ↗

DNA Repair Deficiency and Immunotherapy ResponseSemantic proximity Read ↗

Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysisSemantic proximity Read ↗

Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer.Semantic proximity Read ↗

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Semantic proximity Read ↗

Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.Semantic proximity Read ↗

Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor typesSemantic proximity Read ↗

Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.